End-of-day quote
Bucharest S.E.
03:30:00 26/04/2024 am IST
|
5-day change
|
1st Jan Change
|
1.935
RON
|
+0.26%
|
|
0.00%
|
+38.71%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
326.9
|
341
|
326.3
|
406.8
|
380
|
936.5
|
Enterprise Value (EV)
1 |
452
|
522.1
|
481
|
549.5
|
459.2
|
1,001
|
P/E ratio
|
9.53
x
|
11.1
x
|
12.4
x
|
13.6
x
|
9.87
x
|
11.5
x
|
Yield
|
2.05%
|
5.88%
|
0.68%
|
0.53%
|
1.4%
|
-
|
Capitalization / Revenue
|
0.89
x
|
0.86
x
|
0.94
x
|
1.07
x
|
0.76
x
|
1.52
x
|
EV / Revenue
|
1.23
x
|
1.32
x
|
1.39
x
|
1.45
x
|
0.92
x
|
1.63
x
|
EV / EBITDA
|
7.6
x
|
8.27
x
|
8.08
x
|
9.36
x
|
6.65
x
|
7.99
x
|
EV / FCF
|
-8.07
x
|
-10.2
x
|
11.8
x
|
25.4
x
|
7.71
x
|
-322
x
|
FCF Yield
|
-12.4%
|
-9.81%
|
8.45%
|
3.93%
|
13%
|
-0.31%
|
Price to Book
|
0.69
x
|
0.69
x
|
0.57
x
|
0.67
x
|
0.59
x
|
1.11
x
|
Nbr of stocks (in thousands)
|
6,71,338
|
6,71,338
|
6,71,338
|
6,71,338
|
6,71,338
|
6,71,338
|
Reference price
2 |
0.4870
|
0.5080
|
0.4860
|
0.6060
|
0.5660
|
1.395
|
Announcement Date
|
29/03/19
|
26/03/20
|
09/04/21
|
27/04/22
|
27/04/23
|
17/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
368.7
|
395.1
|
347.2
|
378.8
|
497.3
|
615.3
|
EBITDA
1 |
59.49
|
63.11
|
59.52
|
58.68
|
69.03
|
125.4
|
EBIT
1 |
38.93
|
41.39
|
37.42
|
34.25
|
46.47
|
97.42
|
Operating Margin
|
10.56%
|
10.47%
|
10.78%
|
9.04%
|
9.34%
|
15.83%
|
Earnings before Tax (EBT)
1 |
35.09
|
35.18
|
28.33
|
30.3
|
41.9
|
91.52
|
Net income
1 |
34.3
|
30.82
|
26.39
|
29.94
|
38.51
|
81.09
|
Net margin
|
9.3%
|
7.8%
|
7.6%
|
7.9%
|
7.74%
|
13.18%
|
EPS
2 |
0.0511
|
0.0459
|
0.0393
|
0.0446
|
0.0574
|
0.1208
|
Free Cash Flow
1 |
-56
|
-51.22
|
40.65
|
21.61
|
59.6
|
-3.112
|
FCF margin
|
-15.19%
|
-12.96%
|
11.71%
|
5.71%
|
11.98%
|
-0.51%
|
FCF Conversion (EBITDA)
|
-
|
-
|
68.3%
|
36.84%
|
86.33%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
154.06%
|
72.2%
|
154.74%
|
-
|
Dividend per Share
2 |
0.009992
|
0.0299
|
0.003306
|
0.003198
|
0.007922
|
-
|
Announcement Date
|
29/03/19
|
26/03/20
|
09/04/21
|
27/04/22
|
27/04/23
|
17/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
125
|
181
|
155
|
143
|
79.3
|
64.5
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.102
x
|
2.869
x
|
2.599
x
|
2.431
x
|
1.148
x
|
0.5145
x
|
Free Cash Flow
1 |
-56
|
-51.2
|
40.7
|
21.6
|
59.6
|
-3.11
|
ROE (net income / shareholders' equity)
|
7.71%
|
6.36%
|
4.89%
|
5.06%
|
6.18%
|
10.2%
|
ROA (Net income/ Total Assets)
|
3.8%
|
3.45%
|
2.82%
|
2.43%
|
3.32%
|
5.73%
|
Assets
1 |
901.7
|
893.7
|
934.8
|
1,230
|
1,162
|
1,414
|
Book Value Per Share
2 |
0.7000
|
0.7400
|
0.8600
|
0.9000
|
0.9600
|
1.260
|
Cash Flow per Share
2 |
0
|
0
|
0.0100
|
0
|
0
|
0
|
Capex
1 |
64.6
|
69.2
|
48
|
29.1
|
39.9
|
83
|
Capex / Sales
|
17.52%
|
17.51%
|
13.82%
|
7.67%
|
8.02%
|
13.49%
|
Announcement Date
|
29/03/19
|
26/03/20
|
09/04/21
|
27/04/22
|
27/04/23
|
17/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +38.71% | 279M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|